American Chemical Society--233rd National Meeting. Protein fragment screening in novel drug design. 25-29 March 2007, Chicago, IL, USA.
Bright
Jonathan
J
Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK. jonathan.bright@thomson.com
D000544:Alzheimer Disease / Q000188:drug therapy; D053829:Amyloid Precursor Protein Secretases / Q000187:drug effects; D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology; D016282:Aspartic Acid Endopeptidases / Q000187:drug effects; D016503:Drug Delivery Systems; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology; D006801:Humans; D010446:Peptide Fragments / Q000737:chemistry / Q000494:pharmacology*; D011506:Proteins / Q000494:pharmacology*; D021241:Spectrometry, Mass, Electrospray Ionization / Q000706:statistics & numerical data
D000925:Anticoagulants; D015507:Drugs, Investigational; D006495:Heparin, Low-Molecular-Weight; D010446:Peptide Fragments; D011506:Proteins; D053829:Amyloid Precursor Protein Secretases; D016282:Aspartic Acid Endopeptidases; C509280:BACE1 protein, human